Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata

Psoriasis is an immune-mediated disease characterized by formation of well-demarcated plaques with silver scale. Drugs such as cyclosporine and methotrexate can have deleterious side effects; however, biologic immune modifying agents now provide a safer alternative for psoriasis. Ustekinumab, an interleukin (IL) 12/23 inhibitor, is one such agent and is approved by The US Food and Drug Administration for the treatment of moderate to severe chronic plaque psoriasis. Vitiligo is an acquired autoimmune disorder resulting in depigmented patches of skin.